Journal List > J Korean Bone Joint Tumor Soc > v.17(1) > 1051989

TOOLS
Shin and Kim: Analysis of Treatment Results of Malignant Melanoma
Original Article

J Korean Bone Joint Tumor Soc 2011;17(1):30-35.

Published online: 7 January 2011

DOI: https://doi.org/10.5292/jkbjts.2011.17.1.30

Analysis of Treatment Results of Malignant Melanoma

Duk Seop Shin, Ui Sik Kim

Department of Orthopedic Surgery, Yeungnam University College of Medicine, Daegu, Korea

Correspondence to: Duk Seop Shin, M.D. Department of Orthopedic Surgery, Yeungnam University Hospital, Daemyung-dong, Nam-gu, Daegu 705-717, Korea TEL: +82-53-620-3646 FAX: +82-53-620-4020 E-mail: shinds@med.yu.ac.kr

Received 21 March 201112 May 2011       Accepted 30 May 2011

Copyright © 2011 The Korean Bone and Joint Tumor Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

This study was designed to evaluate the treatment results of malignant melanoma and to analyze the factors influencing prognosis.

Materials and Methods

Thirty one cases of malignant melanoma were included in this study. They were treated in our hospital surgically, medically and immunologically from January 1996 to December 2005, and were followed more than 5 years. We compared 5 year survival rate (5YSR) according to the age, gender, anatomical site, depth of tumor, TNM stage, involvement of lymph node and immuno-chemotherapy.

Results

Overall 5YSR was 80.6%. 5YSR of the age group below 65 years was 89.7% and 66.7% for the age group over 65 (p=0.033). 5YSR for men was 75% and 90.9% for women. 5YSR according to the site of occurrence showed 66.7% in upper extremities, 89.5% in lower extremities, and 66.7% in other site. 5YSR was 100% for the Clark level below III and 62.5% for the level above IV (p=0.032). 5YSR was 53.8% for lymph node metastasis group and 100% for non-lymph node metastasis group (p=0.021).

Conclusion

We concluded that early diagnosis and wide excision was the most important in treatment of malignant melanoma. The prognostic fractors of malignant melanoma were age, depth of tumor (Clark's stage) and metastasis of lymph node.

Keywords: malignant melanoma, treatment results, survival rate, prognostic factor

REFERENCES

1. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin. 2000; 50:215–36.
2. Park JH, Lee HS, Ham DH, Kim JR. An analysis of the prognostic factors of malignant melanoma. J Korean Bone & Joint Tumor Soc. 2009; 15:122–9.
3. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc. 2006; 81:500–7.
crossref
4. Clark WH. A classification of malignant melanoma in man correlated with histiogenesis and biologic behavior. Adv Biol Skin. 1976; 8:621–47.
5. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19:3635–48.
crossref
6. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1790; 172:902–8.
crossref
7. Verma S, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006; 106:1431–42.
crossref
8. Sekulic A, Haluska P, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging mole cular landscape. Mayo Clin Proc. 2008; 83:825–46.
9. Su WP. Malignant melanoma: basic approach to clinicopathologic correlation. Mayo Clin Proc. 1997; 72:267–72.
10. Rhee SK, Kang YK, Park WJ, Chung YG, Lee HJ. Malignant melanoma. J Korean Bone & Joint Tumor Soc. 2001; 7:12–9.
11. Nahabedian MY. Malignant melanoma. Clin Plast Surg. 2005; 32:249–59.

Figure 1.
48 year-old women patient with malignant melanoma on right hand. Wide excision and split skin graft is done over the hand.
jkbjts-17-30f1.tif
Figure 2.
67 year-old man patient with malignant melanoma on left heel. Wide excision and anterolateral thigh free flap is done over the heel.
jkbjts-17-30f2.tif
Figure 3.
50 year-old man patient with malignant melanoma on right 2nd finger. Finger amputation is done.
jkbjts-17-30f3.tif
Figure 4.
Overall cumulative survival curves according to age. Figure 5. Overall cumulative survival curves according to Clark's level.
jkbjts-17-30f4.tif
Figure 5.
Overall cumulative survival curves according to Clark's level.
jkbjts-17-30f5.tif
Figure 6.
Overall cumulative survivial curves according to lymph node metastasis.
jkbjts-17-30f6.tif
Figure 7.
Overall cumulative survivial curves according to TNM stage.
jkbjts-17-30f7.tif
Table 1.
Patients’ Data
Mean age 56.9
Sex (M:F) 20/11
LN meta. 13:+/18:-
Site LE (19), UE (6), Others (6)
Mean F/U (mo.) 46.5

LE, lower extremity; UE, upper extremity; F/U, follow up.

Table 2.
Clark Level, TNM Stage
Clark's level TNM stage
Level I Epidermis (in situ) 3 Stage I L Lesions 1 mm or less in thickness 2
Level II Papillary dermis 8 Stage II L Lesions more than 1 mm 15
Level III Papillary-reticular dermis 4 Stage III R Regional LN (+) 7
Level IV Reticular dermis 10 Stage IV D Distant metastasis 7
Level V Subcutaneous fat 6      
Total   31     31
TOOLS
Similar articles